title: Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.
abstract: Monocyte Chemoattractant Protein-1 (MCP-1) is the first discovered and most extensively studied CC chemokine, and the amount of studies on its role in the etiologies of obesity- and diabetes-related diseases have increased exponentially during the past two decades. This review attempted to provide a panoramic perspective of the history, regulatory mechanisms, functions, and therapeutic strategies of this chemokine. The highlights of this review include the roles of MCP-1 in the development of obesity, diabetes, cardiovascular diseases, insulitis, diabetic nephropathy, and diabetic retinopathy. Therapies that specifically or non-specifically inhibit MCP-1 overproduction have been summarized.
authors: Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, 651 Ilalo Street BSB 222, Honolulu, HI 96813, USA. junchen@hawaii.edu
authors: Jun
authors: J
authors: Panee
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D018932:Chemokine CCL2 / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D048909:Diabetes Complications / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D004358:Drug Therapy / Q000379:methods; D006801:Humans; D009765:Obesity / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D018932:Chemokine CCL2